Cardiac Amyloidosis Trends in Relative Search Volume Data and Patient Safety
Academic Medicine & Surgery · 03.02.2026
DOI: 10.62186/001c.155834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academic Medicine & Surgery, online erschienen am 03.02.2026. Verfasst von Silvia Zervos und 3 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Cardiac amyloidosis (CA), once considered a rare disease, is now being recognized more frequently by cardiologists. This is due in part to the improvement of diagnostic tools. Many patients with Transthyretin amyloid cardiomyopathy (ATTR-CM) travel long distances to a specialized center for the therapeutic interventions they need. This paper followed Doepker et al. (2023) specific formula for using google trends as a potential tool for predicting state demand. The Cardiologist Demand Index (CDI) for each state was developed. Based on the initial findings, states such as North Dakota, South Dakota, and Wyoming could benefit from opening Amyloidosis Treatment Centers in Academic Medical Centers. Amyloidosis Treatment Centers would benefit patients in these states due to the increase in public search inquiries (RSV data), access to clinical trials and research, and new treatments available to patients.
Zitieren
APA
Zervos, S., Turtz, M., Goldstein, J., & Dobbs, M. (2026). Cardiac Amyloidosis Trends in Relative Search Volume Data and Patient Safety. Academic Medicine & Surgery. https://doi.org/10.62186/001c.155834
Vancouver
Zervos S, Turtz M, Goldstein J, Dobbs M. Cardiac Amyloidosis Trends in Relative Search Volume Data and Patient Safety. Academic Medicine & Surgery. 2026. doi:10.62186/001c.155834
BibTeX
@article{Zervos2026,
author = {Zervos, Silvia and Turtz, Michael and Goldstein, Jill and Dobbs, Michael},
title = {Cardiac Amyloidosis Trends in Relative Search Volume Data and Patient Safety},
journal = {Academic Medicine & Surgery},
year = {2026},
doi = {10.62186/001c.155834}
}
EUVIMED